Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Index funds offer a simple, cost-efficient path to retirement growth, combining broad market exposure with minimal management. This overview explains the appeal.
22,512 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Claude Guillemot, a co-founder who built Ubisoft into a global gaming brand, died in a plane crash near La Baule, Fra...
Alphabet signals a strategic pivot as enterprise AI becomes the main growth driver. Google Cloud surges, and a massiv...
Medicare's first round of drug-price negotiations slashes list prices on 10 widely used drugs by up to 79% starting J...
Automation momentum is accelerating, with industry observers warning that robots will replace 700,000 jobs in key sec...
Treat your finances like a health reset. This article delivers four practical tips going financial cleanse to curb sp...
A promising AI-driven play could redefine long-term portfolios. Learn why this stock might be a once-in-a-decade inve...
Rhode Island housing reform advocates take stock after a truncated 2026 session ended without top-priority reform, se...
As AI server demand remains robust, one legacy tech giant stands out as a buy-after-pullback play. This piece weighs ...
Goldfinch outlines a phased wind-down of its Prime unit, shifting from growth to borrower recoveries and testing whet...
Micron Technology has powered higher this year on AI demand, delivering a staggering rally. Yet veteran traders urge ...
World Cup 2026 in the U.S. has sparked a spending spree among fans who travel with dreams of the tournament, even if ...